OR WAIT 15 SECS
While infectious diseases may be dangerous for the general public, they are good news for stock market investors and traders, says a new study from the University of Portsmouth. The study, carried out by Dr. Renatas Kizys from the University’s Portsmouth Business School -- in collaboration with Michael Donadelli and Max Riedel from Goethe University Frankfurt -- showed that large disease-related events of devastating nature to the economy are good news to stock market traders.
The research examined whether investor mood, driven by World Health Organization (WHO) alerts and media news on dangerous infectious diseases, had a significant effect on the stock price of pharmaceutical companies in the United States. By concentrating on irrational investors who buy and sell pharmaceutical companies' stocks guided by beliefs as opposed to rational expectations, the researchers argued that disease-related news (DRNs) should not trigger rational trading.
They found that DRNs lead to sizeable increases in stock prices of pharmaceutical companies. Following the publication of DRNs, stock prices increase more (less) for smaller (larger) pharmaceutical companies, who are less (more) likely to engage in the development of new vaccines in the wake of DRNs. A potential negative investment climate (on the high street) – caused by disease-related fear – does not alter the positive sentiment effect. The balance between the two contrasting effects -- a positive sector-specific sentiment effect and a negative aggregate (fear-induced) effect on the prices of pharmaceutical stocks -- finds the former is quantitatively larger than the latter.
Kizys says, “Based on our research findings, we simulated a number of trading strategies and we found that these strategies can give rise to positive and significant profits. For instance, one such strategy implies that after a DRNs’ publication, it is profitable to sell short futures contracts of the VIX volatility index and buy long a portfolio of pharmaceutical stocks. This trading strategy generates on average a profit from 0.4 percent to 2.0 percent depending on the structure of a pharmaceutical portfolio and the investment horizon (one to three days).”
The study, which was published in the Journal of Financial Markets, was funded by the Portsmouth Business School and the Research Center SAFE (Goethe University Frankfurt).
Source: University of Portsmouth